All In Biotech

Drug Trial Radar · NCT07280702

Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

128

Planned (sponsor's estimate)

Start

Jun 16, 2026

Primary completion

Dec 15, 2027

Study completion Dec 15, 2027

Sponsor

Lead sponsor
University of Texas Southwestern Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life. This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.

Conditions

  • Psoriatic Arthritis (PsA)

Interventions

  • DeucravacitinibDrug

    Drug will be administered in tablet form.

  • PlaceboDrug

    Drug will be administered in tablet form.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients achieving a novel composite endpoint of BSA </= 1 AND SJC </= 1) OR (BSA </= 1 AND TJC </= 1) at 24 weeksTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.